← Back to patent-cliff list
他唑巴坦钠/头孢洛生
Tier C — Watch / tradeTazobactam Sodium/Ceftolozane
默沙东
Originator
2014
First approval
-
Expiry (public)
$0.31B ▲
Peak sales
化学药
Type
Targets：Beta Lactamase、PBP1b、PBP3
Brand：Zerbaxa、卓利达
Indications (approved)：腹腔感染、呼吸机相关性肺炎、泌尿系统感染、社区获得性细菌肺炎、肾盂肾炎、医院获得性肺炎、细菌性肺炎、膀胱炎
Regional status
US
批准上市
2014-12-19
EU
批准上市
2015-09-18
China
批准上市
2025-02-08
Japan
批准上市
2019-01-08
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Tazobactam Sodium/Ceftolozane?
Approved indications include: 腹腔感染, 呼吸机相关性肺炎, 泌尿系统感染, 社区获得性细菌肺炎, 肾盂肾炎, 医院获得性肺炎, 细菌性肺炎, 膀胱炎.
When does the Tazobactam Sodium/Ceftolozane patent expire?
No public expiry year is available for Tazobactam Sodium/Ceftolozane yet; this page updates once verified.
How do I get a quote for Tazobactam Sodium/Ceftolozane intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24